Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer [Phase 2]

View source ↗

Summary

This phase 2 trial update assesses nivolumab with or without ipilimumab in patients with refractory metastatic anal canal cancer, with results posted on 2026-04…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Canal Carcinoma
• Anal Canal Squamous Cell Carcinoma
• Anal Cancer Ajcc V8

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-22